menu
    • menu
    [{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"NTN Buzztime","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Merger","leadProduct":"Cyclophosphamide","moa":"IL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Factor Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Brooklyn ImmunoTherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Brooklyn ImmunoTherapeutics"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Brooklyn ImmunoTherapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Brooklyn ImmunoTherapeutics

    Menu

    Brooklyn ImmunoTherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX-2,Cyclophosphamide,Indomethacin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer

                            Details : IRX-2 is a primary cell-derived multi-cytokine biologic immunotherapy in development for multiple solid tumor indications. IRX-2 is administered locally by subcutaneous injection and is designed to activate T cells to generate an anti-tumor response.

                            Brand Name : IRX-2

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 26, 2022

                            Lead Product(s) : IRX-2,Cyclophosphamide,Indomethacin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

                            Details : The Company intends to use the funds to commence translation of the gene editing, cellular therapy and nanolipid particle platform into its clinical programs with a focus on orphan diseases, like sickle cell anemia, familial amyloidosis and cell therapie...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 24, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Factor Bioscience

                            Deal Size : $1.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Brooklyn Acquires License for mRNA Technology Platform from Factor Bioscience to Treate Multiple Cancers and B...

                            Details : The deal would allow Brooklyn to utilize an extensively patented process to seek to develop gene edited compounds using mRNA, which preclinical data suggest to be more efficient, non-immunogenic and non-mutagenic, for treatment of several solid tumor and...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 15, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Factor Bioscience

                            Deal Size : $1.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Brooklyn ImmunoTherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRX-2,Cyclophosphamide,Indomethacin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : NTN Buzztime

                            Deal Size : $10.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement

                            Details : Proposed merger will create a public company focused on the clinical development program of a cytokine-based product for the treatment of cancer.

                            Brand Name : IRX-2

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 13, 2020

                            Lead Product(s) : IRX-2,Cyclophosphamide,Indomethacin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : NTN Buzztime

                            Deal Size : $10.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth